Bigger drop in systolic BP but less intensification sustainability seen with addition of new med versus maximizing dose of current med
TUESDAY, Oct. 5, 2021 (HealthDay News) — For older adults with hypertension receiving at least one antihypertensive medication at less than the maximum dose, intensification with the addition of a new medication is associated with less intensification sustainability and a slightly larger reduction in mean systolic blood pressure (SBP) than maximizing the dose, according to a study published online Oct. 5 in the Annals of Internal Medicine.
Carole E. Aubert, M.D., from Bern University Hospital in Switzerland, and colleagues examined the frequency of intensification by adding a new medication versus maximizing the dose in a large-scale, population-based retrospective cohort study. Data were included for veterans aged 65 years or older with hypertension, SBP of at least 130 mm Hg, and at least one antihypertensive medication at less than the maximum dose. Among 178,562 patients, 25.5 and 74.5 percent had intensification by adding a new medication and maximizing the dose, respectively.
The researchers found that at three months and 12 months, adding a new medication was associated with less intensification sustainability (average treatment effect, −15.2 and −15.1 percent, respectively) and a larger reduction in mean SBP (−0.8 and −1.1 mm Hg, respectively) compared with maximizing the dose.
“Adding a new medication was associated with greater SBP reduction but less frequent sustained intensification, possibly suggesting that adverse drug events might be more common or patients less willing to take additional medications,” the authors write.
Abstract/Full Text (subscription or payment may be required)
Onset of Mortality, Morbidity Delayed for Offspring of Centenarians
Paternal Exposure to Valproate Not Linked to Offspring Neurodevelopmental Disorders
Chemo-Free Combo of Four Targeted Therapies Shows Promise in Metastatic Breast Cancer
Drug Retention in Spondyloarthritis Varies With Socioeconomic Status
Timing of JAK Initiation, Shingles Vaccine Administration Can Affect Outcomes in RA
Bimekizumab Well Tolerated, Efficacious Over Three Years in Axial Spondyloarthritis
Longer Persistence Seen With Upadacitinib Versus TNFi in Rheumatoid Arthritis
Achieving Low Serum Urate Levels Can Cut Risk for Cardiovascular Events in Gout